Yes. Viking offers fertility-preserving protocols that include HCG (Human Chorionic Gonadotropin) and enclomiphene — either alongside TRT or as standalone treatments. These medications help maintain sperm production while you optimize your testosterone levels, so you do not have to choose between hormone therapy and your reproductive future.
HCG: How It Works
HCG mimics luteinizing hormone (LH), directly stimulating the testes to produce testosterone and maintain sperm production — even when your natural LH is suppressed by exogenous testosterone. Studies show HCG co-administration maintains sperm counts in 70 to 95 percent of men on TRT.
HCG is typically added to an existing TRT protocol. It allows you to keep the full benefits of testosterone therapy while protecting your reproductive function.
Enclomiphene: How It Works
Enclomiphene is the active isomer of clomiphene citrate. Unlike TRT, which supplies testosterone from outside the body, enclomiphene stimulates your body to produce more of its own. It blocks estrogen feedback at the hypothalamus, causing the pituitary to release more LH and FSH. The result: higher testosterone and preserved — sometimes improved — sperm production.
Enclomiphene is ideal for men who want testosterone optimization without any suppression of their natural reproductive function, or as a bridge therapy for men transitioning off TRT.
Which One Is Right for Me?
- Not yet on TRT: Enclomiphene may be the right first step — it raises testosterone without suppressing sperm production at all
- Currently on TRT: Adding HCG can maintain sperm production while you continue testosterone therapy
- Coming off TRT: Enclomiphene can restart your body’s natural LH and FSH signaling
- Actively trying to conceive: Your provider will design a protocol based on your labs and semen analysis
Who This Applies To
Men who want testosterone optimization without sacrificing fertility, men currently on TRT who want to add fertility protection, and men coming off TRT who need to restore natural hormone production.